Joaquim Bellmunt, MD, PhD, Harvard Medical School, Boston, MA, discusses the impact of mutational clonality on patient response to immunotherapies in advanced urothelial carcinoma, stating that higher tumor clonality will predict ameliorated responses to immunotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.